Sponsored by
The Bottom Line Upfront 💡
Brown & Brown $BRO ( ▲ 1.17% ) is a capital-light commission machine that has grown revenue for 31 of the last 32 years. The $9.6B Accession deal juiced headline growth but tanked organic growth to 2.8% and EPS to $3.16. At ~$65, the market may be pricing in too much pessimism — if organic growth rebounds, this looks cheap.
Sponsorship
The first way to trade directly inside Claude and ChatGPT
For decades, the most powerful intelligence lived behind the closed doors of quant firms — billion-dollar funds whose algorithms quietly out-traded everyone else.
That era just ended.
Co-Invest by Liquid is the first way to trade directly inside Claude and ChatGPT. Ask your AI to analyze a market, stress-test an idea, or build a position sized to your comfort level, then execute, right there in the conversation. No jargon. No twelve-screen terminal. No guesswork.
It's built for people who want to invest smarter, not gamble harder. You set the risk tolerance. The AI does the heavy lifting. You approve every trade.
The institutions made the game, Co-Invest gives you a way to beat them.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Think of Brown & Brown as the real estate agent of the insurance world — they don’t own the house (the risk), they just help you buy it and pocket a commission. Founded in Daytona Beach, Florida (yes, the NASCAR town), BRO has grown revenues from $95.6M to $5.9B since 1993 — a 14.2% CAGR that would make most investors weep with joy.
How they make money:
🏷️ Base Commissions (~67% of revenue): A cut of the premium every time they place a policy. A finder’s fee that renews yearly.
💼 Fees (~22% of revenue): Flat fees for claims processing, Medicare advocacy, and F&I products for car dealerships. More predictable than commissions.
🎰 Profit-Sharing Contingent Commissions (~4.4% of revenue): Bonus payments from insurers when loss ratios are favorable. These “good year” bonuses surged 53.6% to $255M in 2025 ↗️.
Two business segments:
Retail (58.7% of revenue): Classic insurance brokerage — commercial, personal, employee benefits. The front door.
Specialty Distribution (41.3% of revenue): The back room where the nerds live. Programs for dentists, flood insurance, excess & surplus lines, captive insurance. Higher margins (43.1% EBITDAC) and growing fast ↗️.
Key internal metrics: Organic Revenue Growth (stripping out acquisitions) and Adjusted EBITDAC Margin. Both are tied to executive pay, so management actually cares about them.
Key Takeaway: BRO is a capital-light commission machine that gets paid every time someone renews their insurance — which they almost always do.
Layer 2: Category Position 🏆
BRO plays in a brutally competitive but wonderfully fragmented industry. The big dogs — Aon, Marsh & McLennan, and Arthur J. Gallagher — have more resources and global reach. But the market is so fragmented that there’s room for everyone, and BRO has been eating smaller players for lunch since 1993 (717 acquisitions and counting 🍽️).
Where BRO wins:
Niche expertise: Arrowhead Programs serves dentists, lawyers, truckers, and municipalities — markets where deep knowledge creates real moats.
Acquisition machine: No one integrates small brokerages faster or more efficiently. A genuine competitive advantage.
Ownership culture: Nearly 20% of the company is employee-owned, and 60%+ participate in the stock purchase plan. Aligned incentives = better service.
Where BRO faces headwinds:
Direct-to-consumer digital platforms are nibbling at personal lines (though BRO’s exposure is limited).
The big four competitors have deeper pockets for mega-deals.
5-year stock return of 73.8% trails the S&P 500 (82.3%) and peer group (83.7%) ↘️ — not a great look.
Key Takeaway: BRO is the best consolidator in a fragmented industry, but it’s not the biggest fish in the pond — and that’s actually fine.
Layer 3: Show Me The Money! 📈
Revenue breakdown (2025):
🇺🇸 U.S.: $5.1B (85.7%)
🇬🇧 U.K.: $599M (10.1%)
🌍 Other International: $244M (4.1%) — growing fast ↗️
Segment margins tell the real story:
Segment | Revenue | EBITDAC Margin |
|---|---|---|
Retail | $3.4B | 30.0% → (flat) |
Specialty Distribution | $2.4B | 43.1% ↗️ |
Specialty Distribution is the golden goose. Higher margins, faster growth, and the Accession acquisition just turbocharged it.
The Accession effect on the P&L:
Total revenue up 22.8% ↗️ — mostly acquisition-driven
Organic growth: only 2.8% (down from 10.4% in 2024) ↘️ — the number that should make you raise an eyebrow
Net income up 6.1% to $1.05B ↗️, but diluted EPS fell to $3.16 from $3.46 ↘️ because they issued 43M new shares to fund the deal
Cost structure:
Employee comp: 49.7% of revenue (slightly improved from 50.1% ↗️)
Interest expense: $297M — up 54% ↗️, the price of borrowing $7.6B
Operating cash flow: $1.45B ↗️ — the business genuinely prints cash
The debt elephant in the room 🐘: Total debt jumped from $3.8B to $7.6B after Accession. Goodwill is now $15.1B — half of total assets. If integrations go sideways, impairment charges could sting.
Key Takeaway: BRO generates exceptional cash flow, but 2025’s headline growth was acquisition-fueled — the real test is whether organic growth rebounds from its 2.8% slump.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Undervalued (if you trust the model) 🟢
Scenario | Fair Value | vs. Current Price (~$65) |
|---|---|---|
Conservative | $128 | +86% |
Optimistic | $209 | +203% |
FMP Model | $200 | +190% |
Key assumptions driving this:
WACC of 6.5–6.8%: BRO has a beta of just 0.60 — a defensive, recession-resistant business. A lower discount rate is appropriate.
Organic growth rebounds to 6–7%: BRO’s 32-year average is 14.2%. Even a partial recovery from 2.8% dramatically changes the math.
FCF margins expand to ~28%: Accession synergies + operating leverage + minimal capex (~1.2% of revenue) = cash flow machine.
At ~$65/share, the market is essentially pricing in a WACC of ~9% or permanent organic growth impairment. That seems harsh for a company that has grown revenue every single year since 1993 except one (2009, and even then it was only -1%).
One-line take: If BRO’s organic growth recovers and Accession integrates cleanly, this stock looks materially cheap.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
Organic growth rebounds from 2.8% back toward 6–8% as the Accession integration stabilizes and insurance markets remain firm
Accession’s $9.6B price tag proves justified through synergies and cross-selling between Risk Strategies and Bridge Specialty Group
BRO’s 32-year compounding track record continues — the acquisition machine keeps running, and Specialty Distribution margins keep expanding
Bear Case 🐻
Organic growth stays depressed, revealing the core business is maturing faster than acquisitions can mask
Accession integration stumbles — $15B in goodwill is a lot of faith in one deal, and integration costs ($113M in 2025 alone) could persist
Insurance market softens, profit-sharing contingent commissions collapse, and rising interest expense ($297M/year) eats into earnings
The Bottom Line: BRO is a genuinely excellent business with a 32-year track record most companies would kill for. The Accession acquisition is a bold bet that reshapes the company — for better or worse, we’ll know more in 12–18 months. At ~$69/share, the market seems to be pricing in a lot of bad news that may not materialize. Long-term investors with patience and a stomach for integration risk have a potentially compelling entry point.
Layer 6: What to Watch 👀
Organic Revenue Growth Rate — The single most important number. Watch for a rebound above 5% in 2026. If it stays below 3%, the bull case gets harder to defend.
Accession Integration Milestones — Management guided $200–300M in synergies. Watch for updates on cost savings, cross-selling wins, and declining integration costs.
Leverage Ratio — Debt-to-equity is elevated post-Accession. Watch for debt paydown; the $400M senior note due in 2026 is the first test.
Profit-Sharing Contingent Commissions — These surged 54% in 2025 on favorable loss ratios. A bad hurricane season could reverse this quickly 🌀.
Specialty Distribution Margins — Currently a stellar 43.1% EBITDAC margin. If newly acquired Accession businesses drag this below 40%, it signals integration friction.
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.